Editor's Picks
There is no pinned content in this Editor's Picks module.
Click here to learn more about content pinning.
-
A major generic drug company in Boucherville has been forced to suspend production of many of its pharmaceutical products and to discontinue the production of other medicines, raising concerns of a possible drug shortage in Quebec. Sandoz Inc. , which emp
-
Multinational generic drug giant Sandoz has suspended or discontinued production of several drugs at its Quebec-based plant following a warning letter from the U.S. Food and Drug Administration, creating new uncertainty for Canadian patients and physicia
-
As investors, we need to understand how our companies truly make their money. A neat trick developed for just that purpose -- the DuPont Formula -- can help us do so. So in this series we let the DuPont Formula do the work. Let's see what the formula can
-
As foreign drug companies began cutting high-paying jobs in Quebec in recent years, Sandoz International GmbH looked like it was bucking the trend. After paying $565-million for Quebec generic drug maker Sabex Holdings in 2004, Sandoz, a division of Swis
-
After more than 30 years of trying to find a major manufacturer to build on the Orkin tract, a deal to bring in Caterpillar came together almost overnight. The nearly 1,000-acre parcel on the Clarke-Oconee county line is considered one of the premier und
-
MONTREAL — A major generic drug company in Boucherville, Que. , has been forced to suspend production of many of its pharmaceutical products and to discontinue the production of other medicines, raising concerns of a possible drug shortage in the province
-
Login or create an account to manage your profile including your email newsletter preferences. Already a paid subscriber? If you are a current, paid subscriber to PRWeek, your login information should have been e-mailed to you at the begining of your sub
-
Le Québec risque de connaître une nouvelle pénurie de médicaments dans les prochains mois. En effet, l'usine québécoise de Sandoz, propriété de la multinationale suisse Novartis, a annoncé un arrêt partiel de sa production.
-
The U.S. Food and Drug Administrat
-
Novartis AG suffered a setback Friday as it was ordered to start printing safety warnings on the packaging of a hypertension drug, aliskiren, that the company had hoped would become a blockbuster. Europe's main drug regulator Friday said it has completed
-
The data on Rasilez's safety risks is coming home to roost. The Novartis ($NVS) blood-pressure drug will get a new warning in Europe at regulators' request, after a recent trial flagged links to stroke and kidney problems. The Swiss drugmaker will revise
-
Pharmaceutical companies are developing a pill containing a biodegradable chip along with the medication to send information on patient's vital statistics to a smartphone, according to a recent article in Chemical and Engineering News. Developed by Calif
-
By Sten Stovall Novartis AG suffered a major setback Friday as it was ordered to start printing safety warnings on the packaging of a hypertension drug, aliskiren, that the company had hoped would become a blockbuster. Europe's main drug regulator Friday
-
New EU contraindication and warnings for Novartis's aliskiren Today Alex Shimmings The CHMP wants changes to the labels of products containing Novartis's troubled anithypertensive aliskiren that will massively curtail its recommended patient population,
-
Novartis AG (NOVN) said it will add a warning to the label for its blood-pressure drug Rasilez in Europe to comply with a request from regulators. Novartis is changing the product information for Rasilez, sold in the U.S. as Tekturna, to say that the dru
-
LONDON Feb 17 (Reuters) - The European Medicines Agency (EMA) is recommending restrictions on the use of aliskiren-containing medicines such as Novartis' blood pressure drug Rasilez after a review found they are not suitable for patients taking certain o
-
While insurance providers and medical instrument producers are very solid investments in the healthcare industry, drug manufacturers tend to get noticed more. These companies are frequently very good investments, combining price growth with attractive di
-
A University of Alberta researcher and Canada Excellence Research Chair in Virology has made the discovery of a vaccine that will potentially help combat hepatitis C. Michael Houghton, who led the team that discovered the hepatitis C virus in 1989, annou
-
On Jan. 8, Novartis Consumer Health, Inc. , announced the voluntary recall of all lots of select bottle sizes of Gas-X Prevention products (expiration dates of Dec. 20, 2013, or earlier) from U.S. retailers. A representative from Novartis noted that only
About Novartis
Wikipedia
Novartis International AG (NYSE: NVS) is a multinational pharmaceutical company based in Basel, Switzerland that manufactures drugs such as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec / Glivec), cyclosporin A (Neoral / Sandimmun), letrozole (Femara), methylphenidate... Full Article
Related Photos
-
Getty Images
BASEL, SWITZERLAND - OCTOBER 25: A general view of Novartis headquarters is seen as trade union members give information to employee on October 25, 2011 in Basel, Switzerland. Novarits announced today it will cut 2000 jobs despite posting a 7 percent increased third-quarter and a net...
View Photo » -
Getty Images
BASEL, SWITZERLAND - OCTOBER 25: A general view of Novartis headquarters is seen on October 25, 2011 in Basel, Switzerland. Novarits announced today it will cut 2000 jobs despite posting a 7 percent increased third-quarter and a net profit of 2.49 billion USD.
View Photo » -
Reuters Pictures
A man walks past the logo of Swiss drugmaker Novartis AG in front of a plant in Basel October 25, 2011. Novartis AG is slashing 2,000 jobs in Switzerland and the United States to keep costs under control in the face of growing price pressures and the strong Swiss franc, the Swiss...
View Photo » -
Reuters Pictures
The Novartis headquarters is seen in Basel in this September 1, 2011 file photo. A strong franc not withstanding, the Swiss pharmaceuticals industry is still stepping up investments in Basel. After 500 years, executives say it will take more than a currency crisis to move them on. To...
View Photo » -
Reuters Pictures
Novartis CEO Joe Jimenez is interviewed in Basel in this September 1, 2011 file photo. A strong franc not withstanding, the Swiss pharmaceuticals industry is still stepping up investments in Basel. After 500 years, executives say it will take more than a currency crisis to move them on.
View Photo » -
AP Photo
This undated product photo provided by Novartis AG, shows the drug Reclast. Food and Drug Administration advisers voted Friday, Sept. 9, 2011 to require makers of widely used osteoporosis drugs to clarify how long patients should take them for the greatest benefit and least risk.
View Photo » -
Reuters Pictures
Novartis CEO Joe Jimenez attends an interview with Reuters at the company's headquarters in Basel September 1, 2011. Growth in emerging markets and trading the rich world up to more advanced implanted lenses are major untapped opportunities for Novartis's eyecare unit Alcon, the Swiss...
View Photo » -
Reuters Pictures
Christoph Brutschin member of the government Canton Basel-Stadt speaks during a news conference in Bern January 17, 2012, on the preservation of the Novartis production site in Nyon/Prangins and the mitigation of the impact on proposed job cuts at the Novartis sites in Basel.
View Photo » -
Reuters Pictures
Pascal Brenneisen, Country President at Novartis Group Switzerland speaks during a news conference in Bern January 17, 2012, on the preservation of the Novartis production site in Nyon/Prangins and the mitigation of the impact on proposed job cuts at the Novartis sites in Basel.
View Photo » -
Reuters Pictures
Pascal Brenneisen (C) Country President at Novartis Group Switzerland speaks next to Philippe Leuba (L) member of the government Canton Vaud and Christoph Brutschin member of the government Canton Basel-Stadt during a news conference on the preservation of the Novartis production site in...
View Photo » -
Reuters Pictures
A general view shows the headquarters of Swiss drugmaker Novartis behind apartment buildings on the borders of the Rhine River in Basel October 29, 2011.
View Photo » -
Reuters Pictures
A cameraman films as police officers secure the access to the villa of Novartis Chairman of the Board Daniel Vasella during a youth faction of the Socialist Party (Juso) "occupy villa Vasella" protest action in Risch near Zug, October 29, 2011. Juso demonstrators gather outside the...
View Photo » -
Reuters Pictures
Workers from a plant of Swiss drugmaker Novartis in the western Swiss town of Nyon shout slogans as they arrive for a demonstration in Basel October 29, 2011. Some thousand participants protested against planned job cuts at Swiss drugmaker Novartis AG and other companies.
View Photo » -
Reuters Pictures
The headquarters of Swiss drugmaker Novartis are seen behind as people carrying flags of Swiss Unia union cross a bridge over the Rhine River during a demonstration in Basel October 29, 2011. Some thousand participants protested against planned job cuts at Swiss drugmaker Novartis AG...
View Photo » -
AP Photo
Novartis Diovan HCT Shellpak Wins HCPC Compliance Package of the Year.
View Photo » -
Reuters Pictures
An employee smokes a cigarette beside the logo of Swiss drugmaker Novartis AG in front of a plant in Basel October 25, 2011. Novartis AG is slashing 2,000 jobs in Switzerland and the United States to keep costs under control in the face of growing price pressures and the strong Swiss...
View Photo » -
Getty Images
BASEL, SWITZERLAND - OCTOBER 25: Employees talk in front of Novartis headquarters on October 25, 2011 in Basel, Switzerland. Novarits announced today it will cut 2000 jobs despite posting a 7 percent increased third-quarter and a net profit of 2.49 billion USD.
View Photo » -
Getty Images
BASEL, SWITZERLAND - OCTOBER 25: An employee looks down as he smokes in front of Novartis headquarters on October 25, 2011 in Basel, Switzerland. Novarits announced today it will cut 2000 jobs despite posting a 7 percent increased third-quarter and a net profit of 2.49 billion USD.
View Photo » -
Reuters Pictures
Traffic signs stand in front of an office building of Swiss drugmaker Novartis AG in Basel October 25, 2011. Novartis AG is slashing 2,000 jobs in Switzerland and the United States to keep costs under control in the face of growing price pressures and the strong Swiss franc, the Swiss...
View Photo » -
AP Photo
People stand in front of the entrance of a Novartis production site in Nyon, Switzerland, Tuesday, Oct. 25, 2011. Swiss pharmaceutical giant Novartis AG posted a 7 percent increase in third-quarter net profit Tuesday as it announced 2,000 job cuts in an effort to save US dollar 200...
View Photo » -
Reuters Pictures
File photo of the headquarters of the drug making company Novartis in Basel January 17, 2008. Swiss drugmaker Novartis AG said October 25, 2011, it is slashing 2,000 jobs in Switzerland and the United States as it seeks to rake in annual savings of more than $200 million in the face of...
View Photo » -
Reuters Pictures
File photo of people walking past the logo of Swiss drugmaker Novartis at the company's plant in Basel January 28, 2009. Swiss drugmaker Novartis AG said October 25, 2011, it is slashing 2,000 jobs in Switzerland and the United States as it seeks to rake in annual savings of more than...
View Photo » -
AP Photo
Joseph Jimenez, CEO, left, and Daniel Vasella, Chairman of Swiss pharmaceutical group Novartis, right, smile as they attend the extraordinary general assembly in Basel, Switzerland, Friday, April 8, 2011. Shareholders vote Friday on a US dollar 51 billion deal to buy Alcon eye care...
View Photo » -
AP Photo
COMMERCIAL IMAGE - In this photo taken by AP Images for Novartis Animal Health US, Mike Rowe, center, shakes hands with U.S. Army veterinarian Col. G.C. Ritchie after announcing a donation to Guardian Angels for Soldier's Pets, in partnership with Sentinel Flavor Tabs (milbemycyn...
View Photo » -
AP Photo
COMMERCIAL IMAGE - In this photo taken by AP Images for Novartis Animal Health US, Mike Rowe and Axl, second left, meet with, from left, Army veterinarian Col. G.C. Ritchie, Air Force Maj. Dave Wilson and Navy Lt. Cdr. Sarah Higgins after announcing a donation to Guardian Angels for...
View Photo »
Getty Images
BASEL, SWITZERLAND - OCTOBER 25: A general view of Novartis headquarters is seen as trade union members give information to employee on October 25, 2011 in Basel, Switzerland. Novarits announced today it will cut 2000 jobs despite posting a 7 percent increased third-quarter and a net...
View Photo »
